Skip to main content

Table 2 Proportion of participants with seroprotection and seroconversion in the various groups

From: Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in infants: randomized, observer-masked, single-center clinical study

Dosage

Age

Baseline

21 days after injection

42 days after injection

 

SP rate (95% CI)

SC rate (95% CI)

SP rate (95% CI)

SC rate (95% CI)

SP rate (95% CI)

15 μg

6-12 m

13.33

26.67

33.33

93.33

93.33

 

(3.73 ~ 37.88)b

(10.90 ~ 51.95)

(15.17 ~ 58.28)

(70.18 ~ 98.81)a

(70.18 ~ 98.81)a

 

13-24 m

32.43

51.35

67.57

94.59

94.59

 

(19.63 ~ 48.53)b

(35.89 ~ 66.55)a

(51.47 ~ 80.37)ab

(82.29 ~ 98.50)a

(82.29 ~ 98.50)a

 

25-35 m

21.05

55.26

65.79

89.47

94.74

 

(11.07 ~ 36.34)

(39.70 ~ 69.85)a

(49.89 ~ 78.79)a

(75.86 ~ 95.83)a

(82.72 ~ 98.55)a

 

Total

24.44

48.89

61.11

92.22

94.44

 

(16.73 ~ 34.24)

(38.82 ~ 59.05)a

(50.78 ~ 70.53)a

(84.80 ~ 96.18)a

(87.64 ~ 97.60)a

7.5 μg

6-12 m

47.37

36.84

63.16

89.47

100.00

 

(27.33 ~ 68.29)

(19.15 ~ 58.96)

(41.04 ~ 80.85)a

(68.60 ~ 97.06)a

(83.18 ~ 100.00)a

 

13-24 m

9.76

34.15

39.02

80.49

82.93

 

(3.86 ~ 22.55)a

(21.56 ~ 49.45)

(25.65 ~ 54.27)

(65.99 ~ 89.77)a

(68.74 ~ 91.48)a

 

25-35 m

19.51

46.34

60.98

87.80

92.68

 

(10.23 ~ 34.01)

(32.05 ~ 61.25)a

(45.73 ~ 74.35)a

(74.45 ~ 94.67)a

(80.57 ~ 97.48)a

 

Total

20.79

39.60

52.48

85.15

90.10

 

(14.02 ~ 29.70)

(30.61 ~ 49.35)a

(42.83 ~ 61.95)a

(76.93 ~ 90.79)a

(82.73 ~ 94.53)a

SI

6-12 m

20.00

0.00

20.00

10.00

30.00

 

(5.67 ~ 50.98)

(0.00 ~ 27.75)

(5.67 ~ 50.98)

(1.79 ~ 40.41)

(10.78 ~ 60.32)

 

13-24 m

11.54

3.85

15.38

3.85

15.38

 

(4.00 ~ 28.98)

(0.68 ~ 18.90)

(6.15 ~ 33.53)

(0.68 ~ 18.90)

(6.15 ~ 33.53)

 

25-35 m

16.00

0.00

16.00

12.00

28.00

 

(6.40 ~ 34.65)

(0.00 ~ 13.32)

(6.40 ~ 34.65)

(4.17 ~ 29.96)

(14.28 ~ 47.58)

 

Total

14.75

1.64

16.39

8.20

22.95

 

(7.96 ~ 25.72)

(0.29 ~ 8.72)

(9.15 ~ 27.61)

(3.55 ~ 17.80)

(14.19 ~ 34.91)

  1. aP < 0.05 compared with the SI group.
  2. bP < 0.05 compared with the 7.5 dose group.